Ranexa Connect®: Helping your patients access Ranexa

Ranexa Connect is a free financial assistance resource for patients with a Ranexa prescription

Our dedicated staff will help investigate affordability and access issues for patients with payment challenges.

Submitting the application is as easy as 1,2,3:

1Download the application form

2Have your patient complete and sign the form, then fill out the remaining diagnosis/medical information required and add your signature

3Fax the application form to Ranexa Connect: 1-888-568-9228

You can also enroll by calling 1-888-726-3925.


See what Ranexa Connect can offer your patients...

With commercial insurance

  • Eligible for the Ranexa Co-pay Coupon Card
    • May reduce eligible patients’ monthly out-of-pocket costs
    • Provides assistance to eligible commercially insured and “cash-pay” patients who are not enrolled in government healthcare prescription drug programs such as Medicare Part D and Medicaid
    • Medicare Part D enrollees, while in the prescription drug coverage gap (the “donut hole”), are still enrolled in Medicare Part D and are not eligible for the co-pay coupon program
    • Patients without insurance coverage or who have commercial insurance that does not cover the Gilead products are considered “cash-pay” patients
    • Read complete Terms and Conditions
  • Help with insurance questions and coordination
    • Research and verify benefits
    • Explain coverage options and policies
    • Explain prior authorization process and research requirements
    • Claims assistance
    • Provide information about the appeals process
  • Help finding alternative financial assistance
    • Evaluate alternate coverage and funding options
    • Advise regarding application requirements
    • May include state assistance programs, Medicaid, Medicare Part D, and charitable foundations

With government insurance, including Medicare Part D

  • Help finding alternative financial assistance
    • Evaluate alternate coverage and funding options
    • Advise regarding application requirements
    • May include state assistance programs, Medicaid, Medicare Part D, and charitable foundations

Without insurance

  • Ranexa provided free of charge for eligible patients through the Patient Assistance Program (PAP)

Support. Access. Savings.
For your patients who need help paying for Ranexa, please direct them to www.MyRanexaConnect.com or ask them to call 1-888-726-3925.

Indication

  • Ranexa (ranolazine) is indicated for the treatment of chronic angina.

Indication

  • Ranexa (ranolazine) is indicated for the treatment of chronic angina.
  • Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.

Important Safety Information

Contraindications

  • Ranexa is contraindicated in patients:
    • Taking strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir)
    • Taking inducers of CYP3A (e.g., rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St John’s wort)
    • With liver cirrhosis

Warnings and Precautions

  • Ranexa blocks lKr and prolongs the QTc interval in a dose-related manner.
  • Clinical experience in an acute coronary syndrome population did not show an increased risk of proarrhythmia or sudden death. However, there is little experience with high doses (> 1000 mg twice daily) or exposure, with other QT-prolonging drugs, with potassium channel variants resulting in a long QT interval, in patients with a family history of (or congenital) long QT syndrome, or in patients with known acquired QT interval prolongation.
  • Acute renal failure has been observed in patients with severe renal impairment while on Ranexa. Monitor renal function after initiation and periodically in patients with moderate to severe renal impairment. Discontinue Ranexa if acute renal failure develops.

Adverse Reactions

  • The most common adverse reactions (> 4% and more common than with placebo) during treatment with Ranexa (ranolazine) were dizziness, headache, constipation, and nausea.

Dosage and Administration

  • Begin treatment with 500 mg twice daily and increase to the maximum recommended dose of 1000 mg twice daily, based on clinical symptoms. Ranexa should be swallowed whole; do not crush, break or chew.
  • Limit the dose of Ranexa to 500 mg twice daily in patients on moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin, fluconazole, and grapefruit juice or grapefruit-containing products). See Drug Interactions for additional dosing considerations.

Drug Interactions

  • Inducers and strong inhibitors of CYP3A: Do not use Ranexa (see Contraindications).
  • Moderate CYP3A inhibitors: Limit Ranexa to 500 mg twice daily (see Dosage and Administration).
  • P-gp inhibitors (e.g., cyclosporine): Ranexa exposure increased; titrate Ranexa based on clinical response.
  • CYP3A substrates: Limit simvastatin to 20 mg once daily when used with Ranexa. Doses of other sensitive CYP3A substrates (e.g., lovastatin) and CYP3A substrates with narrow therapeutic range (e.g., cyclosporine, tacrolimus, sirolimus) may need to be reduced with Ranexa.
  • Drugs transported by P-gp (e.g., digoxin) or metabolized by CYP2D6 (e.g., tricyclic antidepressants and antipsychotics): Doses of these drugs may need to be reduced.
  • Drugs transported by OCT2: Limit metformin to 1700 mg per day when used with Ranexa 1000 mg twice daily. Monitor blood glucose and risks associated with high metformin exposure.

Please see full Prescribing Information for Ranexa (ranolazine).

Graphic indicating user should rotate phone to landscape to view enlarged chart graphic